No difference in immunochemotherapy regimens for follicular lymphoma

Hoping to inch towards a consensus on the best treatment approach or a standard of care for patients with advanced-stage follicular lymphoma, the SWOG cancer research cooperative group and Cancer and Leukemia Group B (CALGB) joined forces to see if among a pair of immunochemotherapy regimens, one was better than the other. They presented an abstract of their findings at the recent ASH conference in San Diego.

The Phase III randomized trial involved 526 patients with previously untreated, advanced stage follicular lymphoma. One arm (N=263) received the current, if unofficial, standard of care, six cycles of R-CHOP, while the other arm (N=263) received six cycles of CHOP followed by radioimmunotherapy in the form of tositumomab / iodine I-131, better known as Bexxar.

Grade 4 hematologic toxicities were fairly equal with 36% experiencing them in the R-CHOP arm and 30% in the CHOP-RIT arm.

Researchers concluded that "no statistically significant differences in progression-free survival (PFS), overall survival (OS), or serious toxicities are yet demonstrable with either regimen administered in this trial. However, PFS and OS are outstanding with either of the two regimens."

In other words, more research will be necessary to determine the benefit, if any, of adding RIT to current chemotherapy for this set of patients.

Source

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphoma.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap